CreatorsPublishersAdvertisers
View more in
Cancer

MRD-Based Consolidation Dara-KRd Elicits Rapid Responses in Newly Diagnosed Myeloma

onclive.com
 2021-09-11

Cover picture for the articleMinimal residual disease–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone was found to induce quick responses and unprecedented rates of MRD negativity in patients with newly diagnosed multiple myeloma. Minimal residual disease (MRD)–based consolidation therapy comprised of daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (dara-KRd) was found...

www.onclive.com

Comments / 0

Comments / 0